Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
MRQ-7, monoclonal
Application:
IHC (p)
Citations:
10
biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
MRQ-7, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (357M-14), vial of 0.5 mL concentrate (357M-15), bottle of 1.0 mL predilute (357M-17), vial of 1.0 mL concentrate (357M-16), bottle of 7.0 mL predilute (357M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
isotype
IgG
control
B-cell lymphoma, tonsil
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic, nuclear
Gene Information
human ... TCL1A(8115)
General description
T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
![]() IVD | ![]() IVD | ![]() IVD | ![]() RUO |
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
TCL1 Positive Control Slides, Product No. 357S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Regulatory Information
监管及禁止进口产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 357M-18 | 0841683138419 |
| 357M-16-RUO | 04061836533588 |
| 357M-17 | 0841683138402 |
| 357M-14 | 0841683138372 |
| 357M-15 | 0841683138389 |
| 357M-16 | 0841683138396 |



